December 8, 2014 / 6:48 AM / 3 years ago

BRIEF-Morphosys announces data from Phase 2a study of MOR208

Dec 8 (Reuters) - Morphosys AG

* Announced promising clinical data on its proprietary drug candidate mor208 from a phase 2a study

* Data show that mor208 is well tolerated with a low level of infusion reactions and demonstrates encouraging single-agent efficacy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below